8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

Solid Tumor Responses – Cell Recruitment, Engagement & Overcoming Immunosuppressive Environment Factors

9:00 am Harnessing NK Cell Engagement for Enhanced Tumor Killing

  • Tony Arulanandam Vice President and Head of Preclinical Research, Cytovia Therapeutics


  • Designing NK cell engagers to enhance their tumor infiltration and anti-tumor response
  • Predicting potential safety issues and toxicology

9:30 am In Vitro and In Vivo Studies Establish DuoBody®-CD3xB7H4 as a Novel Drug Candidate for The Treatment Of Solid Cancers


  • DuoBody®-CD3xB7H4 is an Fc-silenced bispecific antibody designed to induce T-cell mediated cytotoxicity of B7H4+ tumor cells
  • Preclinical and PD biomarker studies suggest DuoBody-CD3×B7H4 enhances T-cell activation, proliferation, and production of cytokines and effector molecules
  • DuoBody®-CD3xB7H4 is currently being investigated in a first-in-human trial for the treatment of solid tumors known to express B7H4

10:00 am Speed Networking & Morning Break


A session dedicated to taking advantage of face-to-face networking time. This an exciting opportunity to get an understanding of who else is overcoming similar challenges within the cell engager space.

11:00 am Roundtable Discussion: Strategy Analysis for Greater Solid Tumor Penetration & More Durable Tumor Killing


At your table, each attendee will have an opportunity to describe and explain one strategy for improving solid tumor responses. This can be based on:

  • Your company’s public information
  • Or your own belief based on the data that you are currently aware of

Following the discussion, we will take 5 minutes for you to engage in debate about the strategies that have been laid out. Your goal will be to pull from this discussion a key learning point that you believe to be unique or particularly important. Finally, we will ask you to write down your key learning(s) which will be collected, compiled, and then released as a post-event report.

11:30 am Improving CD19-targeting T Cell Engagers: The Example of CLN-978


  • A very high-affinity CD19-binding antibody fragment allows targeting lymphoma and leukemia cells expressing very low target levels
  • An albumin-binding single-domain antibody is used as a means to significantly extend serum half life
  • Subcutaneous injection of CLN-978 is a means to significantly lower initial exposure and curb cytokine release

12:00 pm NK Engagement – APX 801

  • Erin Filbert Director of Preclinical Research, Apexigen Inc


  • Improving upon current preclinical development processes
  • Strategies to enhance tumor killing

12:30 pm Networking & Lunch Break

Improving Translatability & Developability

1:30 pm Presentation from Our Expertise Partner, Genoway

  • KADER THIAM Senior Vice President - Discovery Preclinical Models & Services, GenOway

T-Cell Engager Developability – Key Challenges & Hurdles Impeding Fast Acceleration through Early Development

2:00 pm Achieving Strong Avidity & Durability


  • Utilizing the natural features of immunoglobulins to achieve strong binding
  • Looking into the overall developability strengths and weaknesses of IGM based modalities

2:30 pm Afternoon Coffee Break & Poster Session


Join your peers in the cell engager field by presenting your work in our dedicated cell engager poster session. This is the perfect opportunity to discuss, debate, and display your work in the field.

Finding the Right Tools for the Job & Refining Them to Your Needs: Targets, Engagers & Costimulators

3:00 pm Tumor-Targeted Antibody-Anticalin Bispecifics as Potent Costimulatory Molecules


  • Novel costimulators facilitate the generation of multispecific protein formats addressing specific biological modalities
  • Robust and highly selective Anticalin® proteins serving as agonists of costimulatory receptors like 4-1BB
  • Mabcalin™ proteins leverage receptor engagement in immuno-oncology by rational combination with precision targeting

3:30 pm Designing Better Bispecific Development Protocols to Optimize Activity and PK/PD Characteristics


  • With limited preclinical guidance available how can we forge a better path
  • Ensuring we can achieve a reliable binding and tumor-killing

4:00 pm Albumin-Based Biomolecular Multispecifics Designs

  • Ken Howard Associate Professor, Aarhus University

4:30 pm Chair’s Closing Remarks

4:40 pm End of Conference Day One